Centre For Probe Development And Commercialization
Tag
Mar 25, 2024
![OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion](https://oicr.on.ca/wp-content/uploads/2016/03/fusion.jpg)
OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion
Sep 14, 2022
![<strong>New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals</strong>](https://oicr.on.ca/wp-content/uploads/2022/09/NRB-Picture.png)
New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals
Aug 02, 2018
![Ontario centre attracts national attention for probe research, development and commercialization](https://oicr.on.ca/wp-content/uploads/2018/08/CPDC.jpg)
Ontario centre attracts national attention for probe research, development and commercialization
Oct 04, 2017
![FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A](https://oicr.on.ca/wp-content/uploads/2016/03/fusion.jpg)
FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
Feb 23, 2017
![FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation](https://oicr.on.ca/wp-content/uploads/2017/02/oicrfacit_trimmed.jpg)
FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
Oct 05, 2016
![From our Annual Report: Investing in the cure and the economy](https://oicr.on.ca/wp-content/uploads/2016/10/annual-report1.jpg)
From our Annual Report: Investing in the cure and the economy
Mar 16, 2016
![FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic](https://oicr.on.ca/wp-content/uploads/2016/03/fusion.jpg)
FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic
Dec 16, 2015
![FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics](https://oicr.on.ca/wp-content/uploads/2016/11/facit.png)
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
Looking Ahead
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.